HeartBeam Names Ken Persen as Chief Technology Officer
August 04 2022 - 8:45AM
Business Wire
Company Hires Cardiac Industry Veteran to Lead
Technology Development
HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital
healthcare company with a proprietary ECG telemedicine technology
for heart attack detection, announced today the appointment of Ken
Persen to the role of Chief Technology Officer. Persen has
extensive technology, executive and start-up experience in
healthcare and cardiac device industries. He will lead the overall
technology strategy and development of the HeartBeam AIMI™ and
HeartBeam AIMIGo™ platforms.
“I am very excited to join the HeartBeam team and lead the
development of the first-of-its-kind remote 3D vector
electrocardiogram technology,” said Persen. “The promise of
HeartBeam’s technology to substantially change the way that
patients and healthcare professionals manage heart attack symptoms
is even more compelling.”
Persen has over 25 years of experience in the digital healthcare
and cardiac device industries. Most recently, Persen founded
LIVMOR, Inc. a digital health company, where he served as Chief
Technology Officer. Persen began his career in the cardiac rhythm
device industry in software engineering and development roles with
Guidant Corporation and Cameron Health, both subsequently acquired
by Boston Scientific, and then held leadership roles with medical
informatics instruments and systems delivering electronic medical
care, before founding LIVMOR.
“We are very pleased to welcome Ken onto our leadership team,”
said Branislav Vajdic, Ph.D. HeartBeam CEO and founder. “He brings
a deep knowledge of innovation and technology, combined with
industry insights, which will support continued development and
evolution of HeartBeam’s technology.”
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a development stage digital
healthcare company with proprietary ECG telemedicine technology
that will redefine the way high risk cardiovascular patients are
diagnosed in an ambulatory setting at any time and any place. Its
breakthrough solution employs a reusable, credit card sized, 3D
vector ECG recording device and cloud-based software capable of
assisting a physician in diagnosing a wide range of cardiovascular
disease. HeartBeam is initially focusing on a huge unmet need of
helping diagnose heart attacks in patients outside of a medical
institution. No single lead ECG technology can offer this value to
patients and their physicians. This underserved market is several
times larger than the cardiac arrhythmia detection market based on
the prevalence of patients with coronary artery disease at high
risk of heart attack. For more information, visit
www.heartbeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are "forward-looking statements." While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our in our Forms 10-K, 10-Q and other reports filed with the SEC
and available at www.sec.gov. We urge you to consider those risks
and uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220804005591/en/
Media and Investor Relations Contact: Chris Tyson
Executive Vice President MZ North America Direct: 949-491-8235
BEAT@mzgroup.us www.mzgroup.us
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Mar 2024 to Apr 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Apr 2023 to Apr 2024